Novel developments in angiogenesis cancer therapy

Por Hirte, H.W.
Publicado em 2009

Human ovarian carcinoma: evidence for patient-related differences in susceptibility to cytotoxic effectors that attack different cellular subpopulations within a tumour.

Por Clark, D. A., Hirte, H. W., Buick, R. N.
Publicado em 1988

Telomerase activity in human ovarian carcinoma.

Por Counter, C M, Hirte, H W, Bacchetti, S, Harley, C B
Publicado em 1994

Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline

Por Hirte, H., Kennedy, E.B., Elit, L., Fung Kee Fung, M.
Publicado no Curr Oncol (2015)

Optimal chemotherapy treatment for women with recurrent ovarian cancer

Por Fung-Kee-Fung, M., Oliver, T., Elit, L., Oza, A., Hirte, H.W., Bryson, P.
Publicado em 2007

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

Por Raja, F A, Griffin, C L, Qian, W, Hirte, H, Parmar, M K, Swart, A M, Ledermann, J A
Publicado em 2011

A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177

Por Chen, E X, Hotte, S, Hirte, H, Siu, L L, Lyons, J, Squires, M, Lovell, S, Turner, S, McIntosh, L, Seymour, L
Publicado no Br J Cancer (2014)

A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Ma...

Por Mackay, HJ, Buckanovich, RJ, Hirte, H, Correa, R, Hoskins, P, Biagi, J, Martin, LP, Fleming, GF, Morgan, R, Wang, L, Polintan, R, Oza, AM
Publicado em 2011

First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

Por Fu, S., Hirte, H., Welch, S., Ilenchuk, T. T., Lutes, T., Rice, C., Fields, N., Nemet, A., Dugourd, D., Piha-Paul, S., Subbiah, V., Liu, L., Gong, J., Hong, D., Stewart, J. M.
Publicado no Invest New Drugs (2017)

Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

Por Fu, S., Hirte, H., Welch, S., Ilenchuk, T. T., Lutes, T., Rice, C., Fields, N., Nemet, A., Dugourd, D., Piha-Paul, S., Subbiah, V., Liu, L., Gong, J., Hong, D., Stewart, J. M.
Publicado no Invest New Drugs (2017)

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

Por Razak, A R A, Hotte, S J, Siu, L L, Chen, E X, Hirte, H W, Powers, J, Walsh, W, Stayner, L-A, Laughlin, A, Novotny-Diermayr, V, Zhu, J, Eisenhauer, E A
Publicado em 2011

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

Por Duran, I, Kortmansky, J, Singh, D, Hirte, H, Kocha, W, Goss, G, Le, L, Oza, A, Nicklee, T, Ho, J, Birle, D, Pond, G R, Arboine, D, Dancey, J, Aviel-Ronen, S, Tsao, M-S, Hedley, D, Siu, L L
Publicado em 2006

Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer

Por Lee, C K, Simes, R J, Brown, C, Lord, S, Wagner, U, Plante, M, Vergote, I, Pisano, C, Parma, G, Burges, A, Bourgeois, H, Högberg, T, Bentley, J, Angleitner-Boubenizek, L, Ferrero, A, Richter, B, Hirte, H, Gebski, V, Pfisterer, J, Pujade-Lauraine, E, Friedlander, M
Publicado em 2011

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)

Por Sahebjam, S, Bedard, P L, Castonguay, V, Chen, Z, Reedijk, M, Liu, G, Cohen, B, Zhang, W-J, Clarke, B, Zhang, T, Kamel-Reid, S, Chen, H, Ivy, S P, Razak, A R A, Oza, A M, Chen, E X, Hirte, H W, McGarrity, A, Wang, L, Siu, L L, Hotte, S J
Publicado em 2013

Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective

Por Oza, A.M., Castonguay, V., Tsoref, D., Diaz–Padilla, I., Karakasis, K., Mackay, H., Welch, S., Weberpals, J., Hoskins, P., Plante, M., Provencher, D., Tonkin, K., Covens, A., Ghatage, P., Gregoire, J., Hirte, H., Miller, D., Rosen, B., Maroun, J., Buyse, M., Coens, C., Brady, M.F., Stuart, G.C.E.
Publicado em 2011